CLINICAL TRIALS PROFILE FOR TRIAZOLAM
✉ Email this page to a colleague
All Clinical Trials for TRIAZOLAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00671632 ↗ | Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse | Completed | Takeda | Phase 2 | 2003-06-01 | The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse. |
| NCT00695630 ↗ | Flumazenil Reversal of Oral Triazolam | Completed | National Institutes of Health (NIH) | Phase 1/Phase 2 | 2006-09-01 | An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes). |
| NCT00695630 ↗ | Flumazenil Reversal of Oral Triazolam | Completed | University of Washington | Phase 1/Phase 2 | 2006-09-01 | An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes). |
| NCT00894699 ↗ | A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure | Completed | AcelRx Pharmaceuticals, Inc. | Phase 2 | 2009-06-01 | The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction). |
| NCT01017926 ↗ | Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption | Withdrawn | Investigación Farmacológica y Biofarmacéutica | Phase 1 | 2010-08-01 | The purpose of this study is to compare the bioavailability of two oral formulations of Triazolam in healthy volunteers, in order to determine that they are bioequivalent. |
| NCT01017926 ↗ | Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption | Withdrawn | Pfizer | Phase 1 | 2010-08-01 | The purpose of this study is to compare the bioavailability of two oral formulations of Triazolam in healthy volunteers, in order to determine that they are bioequivalent. |
| NCT01159652 ↗ | Hypnotic Medications and Memory: Effect of Drug Exposure During the Night | Completed | American Academy of Sleep Medicine | Phase 4 | 2010-10-01 | The purpose of this study is to determine the effect of two hypnotic medications, zolpidem extended release and zaleplon, on memory. It is expected that a hypnotic with shorter drug duration will allow greater memory consolidation than a hypnotic with longer drug duration. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIAZOLAM
Condition Name
Clinical Trial Locations for TRIAZOLAM
Trials by Country
Clinical Trial Progress for TRIAZOLAM
Clinical Trial Phase
Clinical Trial Sponsors for TRIAZOLAM
Sponsor Name
